Xeris Biopharma’s (XERS) Buy Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Xeris Biopharma (NASDAQ:XERS) in a research report released on Friday morning,Benzinga reports. HC Wainwright currently has a $8.00 price objective on the stock, up from their previous price objective of $6.60. HC Wainwright also issued estimates for Xeris Biopharma’s Q1 2025 earnings at ($0.08) EPS, Q2 2025 earnings at ($0.06) EPS, Q3 2025 earnings at ($0.01) EPS, Q4 2025 earnings at $0.01 EPS and FY2029 earnings at $0.78 EPS.

A number of other equities research analysts have also weighed in on the stock. Jefferies Financial Group restated a “buy” rating and issued a $6.00 price objective (up from $4.00) on shares of Xeris Biopharma in a report on Wednesday, January 29th. Piper Sandler cut Xeris Biopharma from an “overweight” rating to a “neutral” rating and set a $3.00 price target on the stock. in a research note on Monday, November 11th.

Xeris Biopharma Stock Up 2.7 %

NASDAQ:XERS opened at $4.24 on Friday. Xeris Biopharma has a 52 week low of $1.69 and a 52 week high of $4.50. The company has a fifty day simple moving average of $3.57 and a two-hundred day simple moving average of $3.26. The company has a market cap of $632.10 million, a price-to-earnings ratio of -9.42 and a beta of 2.32.

Institutional Investors Weigh In On Xeris Biopharma

Institutional investors have recently modified their holdings of the company. Wealth Enhancement Advisory Services LLC purchased a new stake in Xeris Biopharma in the 3rd quarter valued at approximately $35,000. Connor Clark & Lunn Investment Management Ltd. purchased a new stake in shares of Xeris Biopharma in the third quarter valued at $237,000. Intech Investment Management LLC purchased a new stake in Xeris Biopharma during the 3rd quarter worth about $130,000. Quantbot Technologies LP acquired a new position in Xeris Biopharma in the 3rd quarter valued at about $44,000. Finally, Walleye Capital LLC purchased a new position in Xeris Biopharma in the 3rd quarter valued at about $3,197,000. Hedge funds and other institutional investors own 42.75% of the company’s stock.

Xeris Biopharma Company Profile

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.